Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

NCT03656094 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Pembrolizumab plus chemotherapy
DRUG: Placebo plus chemotherapy

Sponsor

Samsung Medical Center